Login
Home
Charts
Search
Watchlist
Products

Chemfab Alkalis Ltd

CHEMFAB·NSE
354.00-1.48%Tue, 22 Sept '26

Chemfab Alkalis Ltd

CHEMFAB
NSE
354.00
-1.48%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
509Cr
Close
Close Price
354.00
Industry
Industry
Chemicals - Inorganic - Caustic Soda/Soda Ash
PE
Price To Earnings
PS
Price To Sales
1.74
Revenue
Revenue
293Cr
Rev Gr TTM
Revenue Growth TTM
-16.24%
PAT Gr TTM
PAT Growth TTM
95.27%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
808682778284929277687573
Growth YoY
Revenue Growth YoY%
4.72.912.3-3.22.9-3.112.219.6-6.5-18.5-19.0-20.1
Expenses
ExpensesCr
697170687272798071666663
Operating Profit
Operating ProfitCr
11151281012131152910
OPM
OPM%
13.717.615.010.912.414.214.412.37.12.911.413.8
Other Income
Other IncomeCr
122313-912332
Interest Expense
Interest ExpenseCr
000111222222
Depreciation
DepreciationCr
65679101167788
PBT
PBTCr
7118314-75-1-512
Tax
TaxCr
24321222101-4
PAT
PATCr
4751-12-93-2-406
Growth YoY
PAT Growth YoY%
-67.0-52.5-64.5-90.5-112.3-73.5-269.9183.3-279.3-336.7105.2124.7
NPM
NPM%
5.48.26.61.2-0.72.3-9.92.8-2.6-6.50.67.8
EPS
EPS
3.05.03.80.6-0.41.3-6.41.8-1.4-3.10.34.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
808682778284929277687573
Growth YoY
Revenue Growth YoY%
4.72.912.3-3.22.9-3.112.219.6-6.5-18.5-19.0-20.1
Expenses
ExpensesCr
697170687272798071666663
Operating Profit
Operating ProfitCr
11151281012131152910
OPM
OPM%
13.717.615.010.912.414.214.412.37.12.911.413.8
Other Income
Other IncomeCr
122313-912332
Interest Expense
Interest ExpenseCr
000111222222
Depreciation
DepreciationCr
65679101167788
PBT
PBTCr
7118314-75-1-512
Tax
TaxCr
24321222101-4
PAT
PATCr
4751-12-93-2-406
Growth YoY
PAT Growth YoY%
-67.0-52.5-64.5-90.5-112.3-73.5-269.9183.3-279.3-336.7105.2124.7
NPM
NPM%
5.48.26.61.2-0.72.3-9.92.8-2.6-6.50.67.8
EPS
EPS
3.05.03.80.6-0.41.3-6.41.8-1.4-3.10.34.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
205181272331327334311293
Growth
Revenue Growth%
-11.650.222.0-1.22.2-7.0-16.2
Expenses
ExpensesCr
149158215221273291284267
Operating Profit
Operating ProfitCr
55235711054442726
OPM
OPM%
26.912.920.933.316.513.18.88.9
Other Income
Other IncomeCr
01629-399
Interest Expense
Interest ExpenseCr
32101588
Depreciation
DepreciationCr
2520222322362830
PBT
PBTCr
27239893900-3
Tax
TaxCr
11010251373-2
PAT
PATCr
25-8296526-7-30
Growth
PAT Growth%
-132.0453.5124.7-59.2-126.450.695.3
NPM
NPM%
12.4-4.510.619.58.0-2.1-1.1-0.1
EPS
EPS
18.3-5.820.445.618.5-4.9-2.4-0.2
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
205181272331327334311293
Growth
Revenue Growth%
-11.650.222.0-1.22.2-7.0-16.2
Expenses
ExpensesCr
149158215221273291284267
Operating Profit
Operating ProfitCr
55235711054442726
OPM
OPM%
26.912.920.933.316.513.18.88.9
Other Income
Other IncomeCr
01629-399
Interest Expense
Interest ExpenseCr
32101588
Depreciation
DepreciationCr
2520222322362830
PBT
PBTCr
27239893900-3
Tax
TaxCr
11010251373-2
PAT
PATCr
25-8296526-7-30
Growth
PAT Growth%
-132.0453.5124.7-59.2-126.450.695.3
NPM
NPM%
12.4-4.510.619.58.0-2.1-1.1-0.1
EPS
EPS
18.3-5.820.445.618.5-4.9-2.4-0.2

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
14141414141414
Reserves
ReservesCr
262253284347373366361
Current Liabilities
Current LiabilitiesCr
494151469272113
Non Current Liabilities
Non Current LiabilitiesCr
242635217088
Total Liabilities
Total LiabilitiesCr
348335352412500522577
Current Assets
Current AssetsCr
517692124101119127
Non Current Assets
Non Current AssetsCr
297259260288400402450
Total Assets
Total AssetsCr
348335352412500522577
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
14141414141414
Reserves
ReservesCr
262253284347373366361
Current Liabilities
Current LiabilitiesCr
494151469272113
Non Current Liabilities
Non Current LiabilitiesCr
242635217088
Total Liabilities
Total LiabilitiesCr
348335352412500522577
Current Assets
Current AssetsCr
517692124101119127
Non Current Assets
Non Current AssetsCr
297259260288400402450
Total Assets
Total AssetsCr
348335352412500522577

Cash Flow

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
54455593314038
Investing Cash Flow
Investing Cash FlowCr
-58-6-21-48-110-86-81
Financing Cash Flow
Financing Cash FlowCr
3-16-25-9165931
Net Cash Flow
Net Cash FlowCr
-123936-6213-12
Free Cash Flow
Free Cash FlowCr
-4383540-60-71-38
CFO To PAT
CFO To PAT%
213.1-558.7191.0143.4119.1-575.0-1,111.7
CFO To EBITDA
CFO To EBITDA%
98.5195.197.083.858.291.3140.0
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
54455593314038
Investing Cash Flow
Investing Cash FlowCr
-58-6-21-48-110-86-81
Financing Cash Flow
Financing Cash FlowCr
3-16-25-9165931
Net Cash Flow
Net Cash FlowCr
-123936-6213-12
Free Cash Flow
Free Cash FlowCr
-4383540-60-71-38
CFO To PAT
CFO To PAT%
213.1-558.7191.0143.4119.1-575.0-1,111.7
CFO To EBITDA
CFO To EBITDA%
98.5195.197.083.858.291.3140.0

Ratios

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1301773543189221,014423509
Price To Earnings
Price To Earnings
5.112.34.935.0
Price To Sales
Price To Sales
0.61.01.31.02.83.01.41.7
Price To Book
Price To Book
0.50.71.20.92.42.71.11.4
EV To EBITDA
EV To EBITDA
3.08.86.32.917.025.020.124.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.032.334.746.631.529.425.725.7
OPM
OPM%
26.912.920.933.316.513.18.88.9
NPM
NPM%
12.4-4.510.619.58.0-2.1-1.1-0.1
ROCE
ROCE%
9.61.513.124.79.81.01.51.5
ROE
ROE%
9.2-3.09.717.96.8-1.8-0.9-0.9
ROA
ROA%
7.3-2.48.215.75.3-1.3-0.6-0.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1301773543189221,014423509
Price To Earnings
Price To Earnings
5.112.34.935.0
Price To Sales
Price To Sales
0.61.01.31.02.83.01.41.7
Price To Book
Price To Book
0.50.71.20.92.42.71.11.4
EV To EBITDA
EV To EBITDA
3.08.86.32.917.025.020.124.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
44.032.334.746.631.529.425.725.7
OPM
OPM%
26.912.920.933.316.513.18.88.9
NPM
NPM%
12.4-4.510.619.58.0-2.1-1.1-0.1
ROCE
ROCE%
9.61.513.124.79.81.01.51.5
ROE
ROE%
9.2-3.09.717.96.8-1.8-0.9-0.9
ROA
ROA%
7.3-2.48.215.75.3-1.3-0.6-0.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Chemfab Alkalis began in 1985 as a bet that cleaner technology could work in India’s chlor-alkali industry - it became the country’s first plant to adopt membrane cell technology, eliminating mercury at a time when the industry thought it unviable, and that bet eventually rewrote national regulation. Today the company runs two distinct engines from its base in Puducherry: a foundational chemicals business that makes six essential industrial inputs from salt, and a next-generation polymer pipes business built on licensed Spanish technology. The recurring pattern is visible across both - it picks a technology that others consider too hard or too early, absorbs it fully, and then scales it in modular, capital-light increments, whether that means upgrading electrolysers without adding capacity or adding pipe lines that pay back in two years. # Business segments Two engines at different stages - a chlor-alkali cash generator with captive salt and chlorine-consuming derivatives, and a national-scale OPVC pipes platform built on imported technology and government water demand - each scaling in modular steps. ## 1. Chlor-Alkali: the chemical factory that feeds on salt and sunlight **A membrane-cell plant makes six industrial chemicals from seawater salt, with captive salt fields, a chlorine-consuming subsidiary and a three-decade record of process innovation that keeps it running when rivals struggle with chlorine disposal.** - **Salt from its own fields** - the company holds over 1,670 acres of salt pans across two sites in Tamil Nadu, producing industrial-grade salt through natural solar evaporation about 30 km from the main plant, which insulates it from market price swings and ensures consistent raw-material quality. - **Chlorine disposal is the industry’s bottleneck** - caustic soda production always yields chlorine as a co-product, and the company’s ability to run its plant above 80% utilisation rests partly on a wholly owned subsidiary that consumes up to 8,000 tonnes of chlorine annually to make anhydrous aluminium chloride, turning a disposal problem into a value-added product. - **Technology upgrades without capacity bloat** - the plant’s electrolyser fleet was replaced in late 2025 with a new INEOS unit at a cost of about ₹56-57 crore, funded from internal cash, while keeping the licensed capacity flat at 180 tonnes per day; a captive hybrid power plant is set to begin supply in mid-2026, addressing the single largest manufacturing cost. - **A history of world-first process patents** - the company patented a fully enclosed system to contain accidental chlorine leaks, developed a method to make soda ash from flue gas, and most recently patented a way to remove trace iodide from brine, each innovation reducing waste, emissions or input costs in ways that competitors cannot easily copy. - **B2B supply to industries that need alkalis daily** - the six products - caustic soda lye and flakes, liquid chlorine, hydrogen gas, hydrochloric acid and sodium hypochlorite - go into aluminium, paper, soaps, water treatment, steel and pharmaceuticals, with demand linked to alumina capacity expansion in India rather than any single customer. ## 2. OPVC pipes: a plastic pipe that behaves like metal **Oriented PVC pipes are lighter, longer-lasting and smoother than traditional iron pipes, made under exclusive Spanish licence on a plug-and-play line system that lets the company add capacity in 15 days - and government water missions are the buyer.** - **Licensed technology with limited competition** - the company imported the know-how and IP from Molecor Tecnología of Spain in 2018-19 and is one of only seven authorised partners in India, which creates a narrow competitive field for a product that is accepted in 15 states for public water projects. - **A pipe that outperforms ductile iron** - OPVC pipes last over 100 years versus 75 for iron, weigh six to twelve times less, deliver up to 30% more flow because the inner surface is smoother, and do not corrode, which lowers both installation cost and pumping energy over the pipe’s life. - **Plug-and-play capacity addition** - each new production line adds 2,500-3,000 tonnes per annum of capacity, can be operational within 15 days of arrival, and at full utilisation generates ₹45-50 crore in revenue with a payback of roughly two to two-and-a-half years; the company has scaled from one line in 2018 to six operational lines and 20,000 tonnes of annual capacity by Q3FY26. - **Government water missions are the demand engine** - the Jal Jeevan Mission, with a ₹3.6 lakh crore budget to connect rural households to tap water, and AMRUT 2.0, targeting universal urban tap connections and sewerage, have together driven demand, with AMRUT 2.0 alone approving over 1.26 lakh kilometres of new and replacement water pipelines, and OPVC pipes are now specified in tenders across states from Maharashtra to Gujarat. - **A tiny plant footprint with big output** - the Sri City factory runs with just ten permanent staff per shift on the shop floor, operates on a zero-discharge philosophy, and produces pipes from 110 mm to 630 mm in diameter - the only Indian manufacturer capable of the largest size - with 38 quality checks per batch and a BIS certificate for zero failures. # Group structure and partners **The company sits inside the Dr. Rao’s Group with two wholly owned subsidiaries - one that consumes chlorine and one that will house future pipe manufacturing - plus a Spanish technology partnership and a small stake in a renewable power venture.** - **Chemfab Karaikal Limited** - the older subsidiary, incorporated in 2019, operates the 10,000-tonne-per-annum anhydrous aluminium chloride plant that consumes chlorine from the main plant and holds a 65-acre lease at Karaikal for a deferred caustic soda project. - **Chemfab Hiitech Piping Limited** - incorporated in October 2025 as a wholly owned subsidiary, it is intended to manufacture, trade and export OPVC pipes and fittings but had not yet begun operations as of late 2025. - **Molecor Tecnología S.L.** - the Spanish licensor whose technology, know-how and IP were imported in 2018-19 and have been fully absorbed; the partnership limits authorised Indian manufacturers to seven, giving Chemfab a structural barrier to copycat competition. - **Zenataris Renewable Energy** - in May 2026 the company invested ₹14.90 crore for a 3.35% equity stake under a group captive mechanism, securing access to renewable power at lower tariffs for its energy-intensive operations.

Documents — Chemfab Alkalis Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/rv2otwxo2ixqyhmcjg93t3gn.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/3vjvlt8albr409dvdqt5l0wm.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/eox8kp2890w3bbnj613pzmpo.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/py98vzsy92jfhfv5ije2fpf8.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/f7og6i2mg9dqyojeapm4a94v.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/iwja2t3ltb4fzuzjqlb72dvd.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/5rls4jgxytvn84x35so8r4bn.pdf
  • Q1 FY2025 Quarterly Result (Jun 2024, PDF): https://www.stockscans.in/document/aexbtrpbuof3yisc0nltvvtz.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/olptsqj4056ujmu1j1h1d56i.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/xq5ahycvpfjdpg378e7tl86c.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/5cn6kiutm0awtlyufmzxrz49.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/k2h7vx87j6e4he83qxmohkq9.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/efmrqrcfhpwoci5sdtnlb58l.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/fu76z07rttcopub3tmhmhfes.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/scjw0tufidba8wlv7mo85pak.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/lfy0ux27dksg2isada6lzcsd.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/q0yd74sgir56hkvea2e6ax3h.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/0fu8cgxerrlnjbys3ebej090.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/fl0c5de3w0fnrfkav186ero4.pdf